RT - Journal
TY - JOUR
A1 - El-Sheikh, Wafik
A1 - Salim, Gelan
A1 - Afifi, Khaled
A1 - El-Shanawany, Basma
T1 - Safety and efficacy of low-dose alteplase in the treatment of acute ischemic stroke in Egyptian patients
YR - 2016/1/1
JF - Menoufia Medical Journal
JO - Menoufia Med J
SP - 285
OP - 290
VO - 29
IS - 2
UL - http://www.mmj.eg.net/article.asp?issn=1110-2098;year=2016;volume=29;issue=2;spage=285;epage=290;aulast=El;t=5
DO - 10.4103/mmj.mmj_269_19
N2 -
Objective
To evaluate the safety and efficacy of low-dose alteplase (0.6 mg/kg) in the treatment of Egyptian patients with acute ischemic stroke (AIS).
Background
High cost and concerns associated with post-thrombolysis intracerebral hemorrhage are major obstacles that limit utilization of the standard-dose alteplase (0.9 mg/kg) in AIS in Egypt.
Patients and methods
This is a nonrandomized clinical trial conducted on 40 Egyptian patients with AIS who were eligible for intravenous alteplase. Patients were thrombolysed at a dose of 0.6 mg/kg. Primary outcomes were safety expressed in the proportion of patients who developed symptomatic intracranial hemorrhage according to European Cooperative Acute Stroke Study III definition and 3-month mortality and efficacy expressed in the proportion of patients with modified Rankin Scale of 0–1 (favorable outcome) at 3 months.
Results
The proportion of favorable outcome (efficacy analysis) was 37.5% (n = 15). No cases developed symptomatic intracranial hemorrhage in the studied sample with an overall mortality rate of 7.5% (n = 3) with one case recorded in hospital mortality (safety analysis).
Conclusion
Intravenous alteplase at 0.6 mg/kg within 4.5 h of stroke onset could be safe and effective in routine clinical practice as a substitute of the standard dose (0.9 mg/kg) especially in developing countries like Egypt.
ER -